Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Haematologica|February 8, 2006
Chemokine receptor expression in multiple myelomaOrhan Sezer
The Oncologist|March 17, 2009
Myeloma bone disease: recent advances in biology, diagnosis, and treatmentOrhan Sezer
Hematology (Amsterdam, Netherlands)|September 29, 2005
Myeloma bone diseaseOrhan Sezer
Leukemia Research|May 15, 2002
Angiogenesis in multiple myelomaOrhan Sezer, Kathrin Niemöller, Christian Jakob, et al.
Blood|May 15, 2007
Myeloma bone disease and proteasome inhibition therapiesEvangelos Terpos, Orhan Sezer, Peter Croucher, et al.
Leukemia & Lymphoma|April 10, 2008
Novel anti-myeloma agents and angiogenesisKonstantinos Anargyrou, Meletios-Athanassios Dimopoulos, Orhan Sezer, et al.
Cancer Research|January 28, 2004
Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Human bone marrow myeloma cells express RANKLOrhan Sezer, Ulrike Heider, Christian Jakob, et al.
Experimental Cell Research|December 7, 2007
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)Monica Hecht, Ivana von Metzler, Katja Sack, et al.
Investigational New Drugs|March 4, 2005
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-studyPeter Schmid, Marcus Schweigert, Thomas Beinert, et al.
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Haematologica|February 8, 2006
Chemokine receptor expression in multiple myelomaOrhan Sezer
The Oncologist|March 17, 2009
Myeloma bone disease: recent advances in biology, diagnosis, and treatmentOrhan Sezer
Hematology (Amsterdam, Netherlands)|September 29, 2005
Myeloma bone diseaseOrhan Sezer
Leukemia Research|May 15, 2002
Angiogenesis in multiple myelomaOrhan Sezer, Kathrin Niemöller, Christian Jakob, et al.
Blood|May 15, 2007
Myeloma bone disease and proteasome inhibition therapiesEvangelos Terpos, Orhan Sezer, Peter Croucher, et al.
Leukemia & Lymphoma|April 10, 2008
Novel anti-myeloma agents and angiogenesisKonstantinos Anargyrou, Meletios-Athanassios Dimopoulos, Orhan Sezer, et al.
Cancer Research|January 28, 2004
Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Human bone marrow myeloma cells express RANKLOrhan Sezer, Ulrike Heider, Christian Jakob, et al.
Experimental Cell Research|December 7, 2007
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)Monica Hecht, Ivana von Metzler, Katja Sack, et al.
Investigational New Drugs|March 4, 2005
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-studyPeter Schmid, Marcus Schweigert, Thomas Beinert, et al.
Pageof 11